CA2183544A1 - Agent d'application transdermique contenant du desogestrel - Google Patents

Agent d'application transdermique contenant du desogestrel

Info

Publication number
CA2183544A1
CA2183544A1 CA002183544A CA2183544A CA2183544A1 CA 2183544 A1 CA2183544 A1 CA 2183544A1 CA 002183544 A CA002183544 A CA 002183544A CA 2183544 A CA2183544 A CA 2183544A CA 2183544 A1 CA2183544 A1 CA 2183544A1
Authority
CA
Canada
Prior art keywords
desogestrel
estrogen
optionally
penetration
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002183544A
Other languages
English (en)
Inventor
Ralph Lipp
Clemens Gunther
Jutta Riedl
Ulrich Tauber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2183544A1 publication Critical patent/CA2183544A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un agent d'application transdermique se caractérise en ce qu'il contient du desogestrel, le cas échéant associé à un ou deux oestrogènes et à un ou deux renforçateurs miscibles de la pénétration dans un système matriciel, sans adjonction toutefois d'inhibiteurs de la cristallisation.
CA002183544A 1994-02-18 1995-02-09 Agent d'application transdermique contenant du desogestrel Abandoned CA2183544A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4405899A DE4405899A1 (de) 1994-02-18 1994-02-18 Mittel zur transdermalen Applikation enthaltend Desogestrel
DEP4405899.3 1994-02-18

Publications (1)

Publication Number Publication Date
CA2183544A1 true CA2183544A1 (fr) 1995-08-24

Family

ID=6511045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002183544A Abandoned CA2183544A1 (fr) 1994-02-18 1995-02-09 Agent d'application transdermique contenant du desogestrel

Country Status (10)

Country Link
EP (1) EP0744943A1 (fr)
JP (1) JPH09508911A (fr)
KR (1) KR970701538A (fr)
AU (1) AU1578695A (fr)
CA (1) CA2183544A1 (fr)
DE (1) DE4405899A1 (fr)
HU (1) HUT74458A (fr)
NO (1) NO963433L (fr)
NZ (1) NZ279226A (fr)
WO (1) WO1995022321A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195956A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal Hormone Delivery

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600347A1 (de) * 1996-01-08 1997-07-10 Lohmann Therapie Syst Lts Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus
FR2749586B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Inc Nouveaux dispositifs destines a l'administration transdermique de la trimegestone, leur procede de preparation et leur application a titre de medicaments
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
AU2223600A (en) * 1999-01-06 2000-07-24 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
BRPI1003661A2 (pt) * 2010-09-15 2013-01-08 Libbs Farmacêutica Ltda associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195956A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal Hormone Delivery

Also Published As

Publication number Publication date
KR970701538A (ko) 1997-04-12
HU9602286D0 (en) 1996-10-28
EP0744943A1 (fr) 1996-12-04
DE4405899A1 (de) 1995-08-24
NO963433L (no) 1996-08-16
WO1995022321A1 (fr) 1995-08-24
HUT74458A (en) 1996-12-30
JPH09508911A (ja) 1997-09-09
AU1578695A (en) 1995-09-04
NZ279226A (en) 1998-05-27

Similar Documents

Publication Publication Date Title
CA2183543C (fr) Systemes therapeutiques transdermiques contenant des steroides sexuels
AU687013B2 (en) Transdermal application agent containing 3-keto-desogestrel
US5788984A (en) Gestodene-containing agent for transdermal administration
EP0569338B1 (fr) Système d'administration pour l'oestradiol
US5145682A (en) Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5858394A (en) Agent for transdermal administration that contains gestodene esters
CA2227538A1 (fr) Emplatre liberant des hormones
US20060088580A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion
RU2044541C1 (ru) Способ получения лечебного средства для трансдермального применения
CA2183544A1 (fr) Agent d'application transdermique contenant du desogestrel
AU724308B2 (en) Transdermal therapeutic systems that contain sex steroids
JPH07101864A (ja) 経皮吸収貼付剤
JPH09510697A (ja) １４α，１７α−エタノエストラ−１，３，５（１０）−トリエン−３，１７β−ジオールを含有する経皮投与のための薬剤
KR20010029770A (ko) 에스트로겐 작용물질-길항물질을 포함하는 경피 투여용조성물
CA2182188A1 (fr) Substance pour application transdermique contenant du 14.alpha.,17.alpha.-ethanoestra-1,3,5(10)-triene-3,17.beta.-diol

Legal Events

Date Code Title Description
FZDE Discontinued